Compare BCPC & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | KYMR |
|---|---|---|
| Founded | 1967 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 6.8B |
| IPO Year | 1995 | 2020 |
| Metric | BCPC | KYMR |
|---|---|---|
| Price | $169.19 | $79.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 26 |
| Target Price | ★ $176.00 | $108.04 |
| AVG Volume (30 Days) | 139.9K | ★ 699.7K |
| Earning Date | 05-25-2026 | 05-18-2026 |
| Dividend Yield | ★ 0.56% | N/A |
| EPS Growth | ★ 20.87 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $799,023,000.00 | $39,211,000.00 |
| Revenue This Year | $8.28 | $16.05 |
| Revenue Next Year | $4.90 | $4.79 |
| P/E Ratio | $35.87 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $139.17 | $19.45 |
| 52 Week High | $183.90 | $103.00 |
| Indicator | BCPC | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 41.62 |
| Support Level | $165.89 | $77.78 |
| Resistance Level | $170.35 | $95.90 |
| Average True Range (ATR) | 4.85 | 4.58 |
| MACD | -1.68 | -1.57 |
| Stochastic Oscillator | 10.91 | 9.76 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, TYK2, and IRAK4.